"Designing Growth Strategies is in our DNA"

Tardive Dyskinesia Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug (Deutetrabenazine, Valbenazine, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2023-2030

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI107532

 


To get information on various segments, share your queries with us

  ATTRIBUTE

  DETAILS

Study Period

2019-2030

Base Year

2022

Estimated Year

2023

Forecast Period

2023-2030

Historical Period

2019-2021

Growth Rate

CAGR of 9.1% from 2023 to 2030

Unit

Value (USD billion)

Segmentation

By Drug, Distribution Channel, and Region

By Drug

  • Deutetrabenazine
  • Valbenazine
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • U.S. (By Drug, By Distribution Channel)
  • Europe (By Drug, By Distribution Channel, By Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Drug, By Distribution Channel, By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World (By Drug, By Distribution Channel)
  • 2019-2030
  • 2022
  • 2019-2021
  • 101
Download Free Sample

    man icon
    Mail icon
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann